Abstract

To observe the clinical efficacy and safety of alprostadil in combination with the reduced glutathione for the treatment of chronic renal failure patients is the main objective. A total of 98 chronic heart failure patients in this hospital were selected as the subjects and divided into the control group and the observation group, with 49 patients in each group. Patients in the control group received the regular therapy, while those in the observation group received the combined medication of alprostadil and reduced glutathione. Following the treatment, we compared the clinical efficacy, incidence of adverse events and the indicators of renal functions, including the hemoglobin, serum creatinine, 24 h urinary protein and blood urea nitrogen. After treatment, patients in two groups had improvement in the health status, social function, emotional function and mental status, and the improvement in the observation group was superior to that in the control group (all p<0.05). In the observation group, incidence rate of adverse events was 5.4 %, significantly lower than 24.3 % in the control group (p<0.05). Besides, following the treatment, significant improvement was also seen in the indicators of renal functions in two groups and similarly, the improvement in the observation group was more obvious than that in the control group (p<0.05). Alprostadil in combination with reduced glutathione, in treatment of chronic renal failure, can improve the indicators of renal functions, with fewer adverse events, so it is worthy of being promoted in clinical practice.